InxMed

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
FAKSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
March 2027 (1)
IfebemtinibPhase 2Ovarian Cancer Recurrent
Est. primary completion 2027-03-24 · NCT06014528 · CT.gov ↗
What to watch
December 2027 (1)
IfebemtinibPhase 1/2Solid Tumor
Est. primary completion 2027-12-31 · NCT06166836 · CT.gov ↗
What to watch
2028 (1)
September 2028 (1)
IfebemtinibPhase 3Non-Small Cell Lung Cancer
Est. primary completion 2028-09 · NCT07174908 · CT.gov ↗
What to watch
2031 (1)
February 2031 (1)
IfebemtinibPhase 1/2Solid Tumor Cancer, PDAC
Est. primary completion 2031-02-28 · NCT07441174 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.